MedPath

A Study of Gaboxadol in Primary Insomnia

Phase 3
Completed
Conditions
Primary Insomnia
Registration Number
NCT00209963
Lead Sponsor
H. Lundbeck A/S
Brief Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Detailed Description

To obtain long-term safety and tolerability data with gaboxadol.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria
  • patients with Primary insomnia
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Long-term safety in gaboxadol.
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.